Table 3.
Incidence of Radiation-Associated Lower Cranial Neuropathies in Published Cohorts
| Lower Cranial Neuropathies | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Study | n | Site of Disease | Treatment | Boost (+/−) | IX | X | XII | Any | Multiple |
|
| |||||||||
| Retrospective Cohorts | |||||||||
| He [31] | 158 | NP | Accelerated fractionation, total dose of 78 Gy/60 fx/6 weeks | + | − | 7% | 7% | 11% | 4% |
| Jaruchinda [4] | 70 | NP, OP, HP, OC, O | 1.8–2 Gy/fx/day total dose 44–50 Gy for N0, total dose 66–70 Gy for N1 & N2, 1 pt with RICNP received CRT | − | − | 10% | − | 10% | − |
| King [5] | 234 | NP | ≥ 66 Gy, 2 Gy/fx/day or 1.6 Gy/2 fx/day Boost |
+ | − | 1.71% | 5.98% | 5.98% | 1.71% |
| Kong[23] | 317 | NP | Technique A: median dose 71 Gy Technique B: median dose 61 Gy Boost |
+ | − | − | − | 25.6% (total from Technique A and B) | − |
| Luk [17] | 965 | NP | 70 Gy, boost 16.7%, CRT 58.3% | − | − | − | 3.1% | 3.7% | − |
| Rong [22] | 307 | NP | 60-80 Gy 1 fx/day | − | 19% | 12% | 23% | 20% | |
| Schinagl [16] | 117 | NP | 2Gy/fx/day, or 70Gy + 7 Gy boost, or endocavitary boost dose of 12 Gy, or neoadjuvant chemotherapy | + | 1% | − | 10% | 20.5% | 4.3% |
| Teo [18] | 159 | NP | Arm I: conventional 2D 61Gy/24 fx Arm II: 2D hyperfractionation 71Gy 2/40 + 14 Gy boost |
+ | − | − | − | Arm I: 8.7% Arm II: 13.0% Total LCNP: 11.0% |
− |
| Chen [32] | 316 | NP | >66 Gy ± weekly cisplatin | − | − | − | − | RT: 2.53% CRT: 6.33% |
− |